I'm LongbridgeAI, I can summarize articles.LifeSci Capital reiterated a Buy rating on BlossomHill Therapeutics with a $32 price target, citing strong Phase 1/2 data for BH-30643 in C797S-mutant patients. Guggenheim also initiated coverage with a Buy rating and a $30 target.
In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on BlossomHill Therapeutics, Inc., with a price target of $32.00.
Charles Zhu has given his Buy rating due to a combination of factors, most notably the emerging clinical profile of BH-30643 from the SOLARA Phase 1/2 study in C797S-mutant patients. The updated WCLC 2026 data show a maintained overall response rate in the mid-40% range, alongside encouraging treatment durability with most patients remaining on therapy at roughly seven months of median follow-up, which supports confidence in the drug’s efficacy trajectory.
Safety findings, including liver-related laboratory abnormalities, appear consistent with expectations and manageable, with no Hy’s Law cases observed, reinforcing the therapeutic window for BH-30643. Together with a clear path toward a C797S-focused accelerated approval discussion in late 2026 and a discounted cash flow valuation that supports an unchanged $32 price target, Zhu views BlossomHill’s risk-reward profile favorably and sees meaningful upside potential in the shares.
In another report released on September 1, Guggenheim also initiated coverage with a Buy rating on the stock with a $30.00 price target.